Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors

Details for Australian Patent Application No. 2004263306 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Nettekoven, Matthias Heinrich; Stalder, Henri; Narquizian, Robert; Norcross, Roger David; Pinard, Emmanuel; Jolidon, Synese

Agent Spruson & Ferguson

Pub. Number AU-B-2004263306 (Modified Examination)

PCT Pub. Number WO2005/014563

Priority 03017614.3 11.08.03 EP

Filing date 2 August 2004

Wipo publication date 17 February 2005

Acceptance publication date 22 April 2010

International Classifications

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

C07D 213/85 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 239/42 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 241/20 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

C07D 251/42 (2006.01) Heterocyclic compounds containing 1,3,5-triazine rings

C07D 257/04 (2006.01) Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms

C07D 263/32 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

C07D 271/06 (2006.01) Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms

C07D 295/192 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

C07D 309/12 (2006.01) Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings

Event Publications

23 February 2006 PCT application entered the National Phase

  PCT publication WO2005/014563 Priority application(s): WO2005/014563

13 April 2006 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 02 Mar 2006

22 April 2010 Application Accepted

  Published as AU-B-2004263306 (Modified Examination)

19 August 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004263311-2-amino-5-benzoylthiazole NPY antagonists

2004263303-RA antigenic peptides